There is widespread expectation that artificial intelligence (AI) will revolutionize nearly every aspect of health care over the next decade. However, when it comes to applying AI to pharmaceutical R&D use cases, there have been as many setbacks as there have been successes. While it seems AI is gaining traction in operational and clinical applications, success in research and innovation has been more elusive. For example, we have seen encouraging signs in the prediction of protein folding, while highly publicized efforts in pathway prediction have come to naught.

This session will explore roadblocks to successfully implementing these emerging technologies to boost biopharma R&D pipelines, and it will identify strategic imperatives to guide smart investments that can help organizations overcome those challenges. Moderated by Kathy Gibson, chief innovation officer of CAS, a specialist in scientific information solutions, and featuring leading executives, the session will emphasize actionable strategic approaches for individual organizations and the industry as a whole.